Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Novartis
Daiichi Sankyo
Chinese Patent Office
Accenture
Fish and Richardson
QuintilesIMS
Dow
Harvard Business School
Citi

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,404,703

« Back to Dashboard

Which drugs does patent 8,404,703 protect, and when does it expire?

Patent 8,404,703 protects EFFIENT and is included in one NDA.

Protection for EFFIENT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-six countries.
Summary for Patent: 8,404,703
Title:Medicinal compositions containing aspirin
Abstract: A combination of 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.
Inventor(s): Asai; Fumitoshi (Nishitokyo, JP), Sugidachi; Atsuhiro (Kawasaki, JP), Ogawa; Taketoshi (Tokyo, JP), Inoue; Teruhiko (Ube, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:11/520,168
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,404,703

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,404,703

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-392983Dec 25, 2000

Non-Orange Book US Patents Family Members for Patent 8,404,703

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,569,325 Method of treatment with coadministration of aspirin and prasugrel ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,404,703

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I293249 ➤ Sign Up
Slovakia 287972 ➤ Sign Up
Slovakia 7542003 ➤ Sign Up
Russian Federation 2262933 ➤ Sign Up
Portugal 1350511 ➤ Sign Up
Poland 206138 ➤ Sign Up
Poland 363183 ➤ Sign Up
New Zealand 526540 ➤ Sign Up
Norway 20032902 ➤ Sign Up
Mexico PA03005770 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fuji
Harvard Business School
UBS
QuintilesIMS
Chubb
Colorcon
Deloitte
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot